Inovio Pharmaceuticals, Inc. (NASDAQ:INO)’s share price fell 4% during trading on Tuesday . The company traded as low as $4.20 and last traded at $4.55. 1,198,900 shares changed hands during trading, a decline of 6% from the average session volume of 1,281,272 shares. The stock had previously closed at $4.74.
Several research firms have commented on INO. Aegis reiterated a “buy” rating and set a $14.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, October 6th. Citigroup Inc. assumed coverage on shares of Inovio Pharmaceuticals in a research report on Friday, October 6th. They set a “buy” rating and a $10.00 price target for the company. Zacks Investment Research downgraded shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, BidaskClub downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $19.16.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.15). The company had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. Inovio Pharmaceuticals’s revenue was down 79.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.28) earnings per share. analysts expect that Inovio Pharmaceuticals, Inc. will post -1.08 EPS for the current year.
The company also recently disclosed a monthly dividend, which was paid on Monday, October 16th. Investors of record on Friday, September 29th were given a dividend of $0.069 per share. The ex-dividend date was Thursday, September 28th. This represents a $0.83 dividend on an annualized basis and a yield of 18.20%.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virginia Retirement Systems ET AL acquired a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at about $101,000. BlueCrest Capital Management Ltd acquired a new position in Inovio Pharmaceuticals during the 2nd quarter worth approximately $107,000. Engineers Gate Manager LP acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth approximately $117,000. Emerald Advisers Inc. PA raised its stake in Inovio Pharmaceuticals by 84.0% during the 3rd quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 9,280 shares during the period. Finally, First Interstate Bank raised its stake in Inovio Pharmaceuticals by 291.9% during the 3rd quarter. First Interstate Bank now owns 24,300 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 18,100 shares during the period. Hedge funds and other institutional investors own 24.98% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2017/11/14/inovio-pharmaceuticals-inc-ino-stock-price-down-4.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.